Inozyme Pharma, Inc.

Historical 13F Holders

Symbol
INZY
CUSIP
45790W108
All holders as of
Q2 2025
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 45790W108 since 12/18/2024, largest first.

Filer % of Class Filed
Glazer Capital, LLC 13G
6.6% 6/4/2025
Event 5/28/2025
Under 5%, checked the "5 percent or less" box, or amended by a later filing (8)
BlackRock, Inc. 13G/A 4.1% 7/17/2025
Event 6/30/2025
Eventide Asset Management, LLC 13G/A
3.5% 4/23/2025
Event 12/31/2024
Affinity Asset Advisors, LLC 13G/A
2.9% 5/30/2025
Event 5/20/2025
Adage Capital Management, L.P. 13G/A
0% 8/12/2025
Event 6/30/2025
Beryl Capital Management LLC 13G/A
0% 8/14/2025
Event 6/30/2025
Pivotal bioVenture Partners Fund I, L.P. 13D/A
0% 8/27/2025
Event 7/1/2025
Rock Springs Capital Management LP 13G/A
0% 8/13/2025
Event 6/30/2025
Samlyn Capital, LLC 13G/A
0% 2/14/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2025 Q2 91 50.6 M $202 M
2025 Q1 100 46.7 M $42.5 M
2024 Q4 108 52.4 M $145 M
2024 Q3 93 54.6 M $286 M
2024 Q2 96 53.9 M $241 M
2024 Q1 96 50.2 M $384 M
2023 Q4 88 50.6 M $216 M
2023 Q3 84 48.7 M $205 M
2023 Q2 79 34.2 M $190 M
2023 Q1 55 32.0 M $183 M
2022 Q4 39 29.0 M $30.5 M
2022 Q3 41 31.5 M $84.6 M
2022 Q2 48 31.5 M $149 M
2022 Q1 51 17.4 M $71.2 M
2021 Q4 52 17.3 M $118 M
2021 Q3 53 17.5 M $203 M
2021 Q2 51 19.8 M $337 M
2021 Q1 56 19.2 M $379 M
2020 Q4 55 18.4 M $379 M
2020 Q3 54 16.3 M $429 M